Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11471880 | 0.85 | ACLY (0.48) | IDO1CYP3A4MAPK1CYP1A2CYP2C9 | |
| SCHEMBL12562215 | 0.84 | TP53 (0.39) | IDO1CYP3A4MAPK1CYP1A2CYP2C9 | |
| SCHEMBL14217011 | 0.82 | PSEN1 (0.35) | IDO1CYP3A4MAPK1CYP2C9CYP2C19 | |
| SCHEMBL19481165 | 0.81 | GGPS1 (0.31) | IDO1CYP3A4MAPK1SMN1; SMN2MEN1 | |
| SCHEMBL21404199 | 0.81 | PYCR1 (0.44) | MAPK1MEN1SLC6A4KMT2AKCNH2 | |
| SCHEMBL30632028 | 0.81 | PYCR1 (0.44) | MAPK1MEN1SLC6A4KMT2AKCNH2 | |
| SCHEMBL11621292 | 0.80 | IDO1 (0.65) | IDO1CYP3A4MAPK1CYP1A2CYP2C9 | |
| SCHEMBL6886022 | 0.79 | GGPS1 (0.55) | IDO1CYP3A4MAPK1CYP1A2CYP2C9 | |
| SCHEMBL16302165 | 0.79 | ACLY (0.53) | ACLYCNR1 | |
| SCHEMBL426435 | 0.77 | IDO1 (0.56) | IDO1CYP3A4MAPK1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20210186970-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | NORTHWESTERN UNIVERSITY | 2021-06-24 | — | — | US | disclosed |
| US-20190167685-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | NORTHWESTERN UNIVERSITY | 2019-06-06 | — | — | US | disclosed |
| US-20170355700-A1 | PYRAZOLOPYRIMIDINE ANTIBACTERIAL AGENTS | NORTHERN ILLINOIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| US-20170355700-A1 | PYRAZOLOPYRIMIDINE ANTIBACTERIAL AGENTS | NORTHERN ILLINOIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| US-20160310491-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | NORTHWESTERN UNIVERSITY | 2016-10-27 | — | — | US | disclosed |
| US-9428467-B2 | Selective calcium channel antagonists | NORTHWESTERN UNIVERSITY (US) | 2016-08-30 | — | — | US | disclosed |
| US-9201014-B2 | Development of photostable near-IR cyanine dyes for in vivo imaging | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2015-12-01 | — | — | US | disclosed |
| US-9149463-B2 | Methods and compositions of treating a Flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY (US) | 2015-10-06 | — | — | US | disclosed |
| US-9101628-B2 | Methods and composition of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-08-11 | — | — | US | disclosed |
| US-7816377-B2 | Tubulysin analogues | R&D-BIOPHARMACEUTICALS GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| US-20100015093-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-01-21 | — | — | US | disclosed |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-7598247-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167685-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | CACNA1C, CACNA1B, CACNA1G | IDO1 3172/4885CYP3A4 4746/4885MAPK1 2881/4885 |
| US-20160310491-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | CACNA1C, CACNA1B, CACNA1G | IDO1 3172/4885CYP3A4 4746/4885MAPK1 2881/4885 |
| US-20100015093-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | IDO1 2519/4885CYP3A4 2026/4885MAPK1 4363/4885 |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | IDO1 2671/4885CYP3A4 463/4885MAPK1 4561/4885 |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | IDO1 280/4885CYP3A4 2121/4885MAPK1 2034/4885 |
| US-20170355700-A1 | PYRAZOLOPYRIMIDINE ANTIBACTERIAL AGENTS | DHPS, FDPS, IMPDH1 | IDO1 791/4885CYP3A4 73/4885MAPK1 448/4885 |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | CFD, CFH, TFPI | IDO1 4649/4885CYP3A4 2309/4885MAPK1 824/4885 |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | IDO1 280/4885CYP3A4 2121/4885MAPK1 2034/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | IDO1 208/4885CYP3A4 2109/4885MAPK1 2194/4885 |
| US-20210186970-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | CACNA1C, CACNA1B, CACNA1G | IDO1 3172/4885CYP3A4 4746/4885MAPK1 2881/4885 |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | IDO1 2519/4885CYP3A4 2026/4885MAPK1 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.